{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:52:28Z","timestamp":1793832748130,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 PCA214278C"],"award-info":[{"award-number":["P01 PCA214278C"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01\/37-CA262362-01A1"],"award-info":[{"award-number":["R01\/37-CA262362-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012200","name":"Laffey-McHugh Foundation","doi-asserted-by":"publisher","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}],"id":[{"id":"10.13039\/100012200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012200","name":"Laffey-McHugh Foundation","doi-asserted-by":"publisher","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}],"id":[{"id":"10.13039\/100012200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011619","name":"Society for Immunotherapy of Cancer","doi-asserted-by":"publisher","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}],"id":[{"id":"10.13039\/100011619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["2329-20"],"award-info":[{"award-number":["2329-20"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41591-024-02826-w","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:25:06Z","timestamp":1706106306000},"page":"984-989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":278,"title":["T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy"],"prefix":"10.1038","volume":"30","author":[{"given":"Guido","family":"Ghilardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8993","authenticated-orcid":false,"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Gerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7400-9097","authenticated-orcid":false,"given":"Vivianna M.","family":"Van Deerlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J. D.","family":"Morrissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7763-2458","authenticated-orcid":false,"given":"Gabriel C.","family":"Caponetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaryse C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-1625","authenticated-orcid":false,"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2518","authenticated-orcid":false,"given":"Sandra P.","family":"Susanibar Adaniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ositadimma H.","family":"Ugwuanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0273-1316","authenticated-orcid":false,"given":"Eugenio","family":"Fardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0324-5367","authenticated-orcid":false,"given":"Emeline R.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrutti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymone","family":"Pajarillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kulikovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-8465","authenticated-orcid":false,"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"2826_CR1","unstructured":"US FDA. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous (2023)."},{"key":"2826_CR2","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood-2011-12-381426","volume":"119","author":"A Thomas","year":"2012","unstructured":"Thomas, A. et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 119, 2731\u20132737 (2012).","journal-title":"Blood"},{"key":"2826_CR3","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/jnci\/85.23.1932","volume":"85","author":"LB Travis","year":"1993","unstructured":"Travis, L. B. et al. Second cancers among long-term survivors of non-Hodgkin\u2032s lymphoma. J. Natl Cancer Inst. 85, 1932\u20131937 (1993).","journal-title":"J. Natl Cancer Inst."},{"key":"2826_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3324\/haematol.12120","volume":"93","author":"S Sacchi","year":"2008","unstructured":"Sacchi, S. et al. Secondary malignancies after treatment for indolent non-Hodgkin\u2032s lymphoma: a 16-year follow-up study. Haematologica 93, 398\u2013404 (2008).","journal-title":"Haematologica"},{"key":"2826_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4132\/jptm.2021.10.09","volume":"56","author":"HN Kim","year":"2022","unstructured":"Kim, H. N. et al. Composite follicular lymphoma and classic Hodgkin lymphoma. J. Pathol. Transl. Med. 56, 57\u201360 (2022).","journal-title":"J. Pathol. Transl. Med."},{"key":"2826_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3960\/jslrt.16020","volume":"57","author":"Y Aoyama","year":"2017","unstructured":"Aoyama, Y. et al. Plasmablastic lymphoma with unfavorable chromosomal abnormalities related to plasma cell myeloma: A borderline case between plasmablastic lymphoma and plasmablastic plasma cell myeloma. J. Clin. Exp. Hematop. 57, 37\u201339 (2017).","journal-title":"J. Clin. Exp. Hematop."},{"key":"2826_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.2020010497","volume":"138","author":"D Chihara","year":"2021","unstructured":"Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138, 785\u2013789 (2021).","journal-title":"Blood"},{"key":"2826_CR8","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld, M. et al. Second cancer risk up to 40 years after treatment for Hodgkin\u2032s lymphoma. N. Engl. J. Med. 373, 2499\u20132511 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2826_CR9","first-page":"472","volume":"11","author":"H Goel","year":"2021","unstructured":"Goel, H. et al. Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. Am. J. Blood Res. 11, 472\u2013497 (2021).","journal-title":"Am. J. Blood Res."},{"key":"2826_CR10","doi-asserted-by":"crossref","first-page":"20180390","DOI":"10.1259\/bjr.20180390","volume":"92","author":"C Demoor-Goldschmidt","year":"2019","unstructured":"Demoor-Goldschmidt, C. & de Vathaire, F. Review of risk factors of secondary cancers among cancer survivors. Br. J. Radiol. 92, 20180390 (2019).","journal-title":"Br. J. Radiol."},{"key":"2826_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41409-018-0290-6","volume":"54","author":"E Martelin","year":"2019","unstructured":"Martelin, E. et al. Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up. Bone Marrow Transpl. 54, 334\u2013337 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"2826_CR12","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","volume":"7","author":"BK Ragon","year":"2023","unstructured":"Ragon, B. K. et al. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 7, 2746\u20132757 (2023).","journal-title":"Blood Adv."},{"key":"2826_CR13","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","volume":"23","author":"JR Brown","year":"2005","unstructured":"Brown, J. R. et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin\u2032s lymphoma. J. Clin. Oncol. 23, 2208\u20132214 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2826_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong, E. A., Ruella, M., Schuster, S. J. & Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 384, 673\u2013674 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2826_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao, W. H. et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 15, 86 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2826_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro, A. et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol. Blood Marrow Transpl. 26, 26\u201333 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2826_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2022015728","volume":"140","author":"DHM Steffin","year":"2022","unstructured":"Steffin, D. H. M. et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood 140, 16\u201324 (2022).","journal-title":"Blood"},{"key":"2826_CR18","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805\u20133815 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2826_CR19","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"2826_CR20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"key":"2826_CR21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood.2021010813","volume":"138","author":"DC Bishop","year":"2021","unstructured":"Bishop, D. C. et al. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood 138, 1504\u20131509 (2021).","journal-title":"Blood"},{"key":"2826_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"2826_CR23","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 3, 2317\u20132322 (2019).","journal-title":"Blood Adv."},{"key":"2826_CR24","doi-asserted-by":"publisher","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).","journal-title":"Sci. Transl. Med."},{"key":"2826_CR25","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 142, 6939 (2023).","journal-title":"Blood"},{"key":"2826_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/jcmm.17196","volume":"26","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Ao, X., Zhou, X., Du, C. & Kuang, S. The regulation of PBXs and their emerging role in cancer. J. Cell. Mol. Med. 26, 1363\u20131379 (2022).","journal-title":"J. Cell. Mol. Med."},{"key":"2826_CR27","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/mt.2013.67","volume":"21","author":"T Heinrich","year":"2013","unstructured":"Heinrich, T. et al. Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol. Ther. 21, 1160\u20131168 (2013).","journal-title":"Mol. Ther."},{"key":"2826_CR28","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","volume":"5","author":"PG Miller","year":"2021","unstructured":"Miller, P. G. et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 5, 2982\u20132986 (2021).","journal-title":"Blood Adv."},{"key":"2826_CR29","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1097\/HS9.0000000000000957","volume":"7","author":"V Panagiota","year":"2023","unstructured":"Panagiota, V. et al. Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients. Hemasphere 7, e957 (2023).","journal-title":"Hemasphere"},{"key":"2826_CR30","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","volume":"6","author":"R Teipel","year":"2022","unstructured":"Teipel, R. et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 6, 1941\u20131946 (2022).","journal-title":"Blood Adv."},{"key":"2826_CR31","doi-asserted-by":"publisher","first-page":"e000104","DOI":"10.1136\/jitc-2019-000104","volume":"8","author":"K Anand","year":"2020","unstructured":"Anand, K. et al. T-cell lymphoma secondary to checkpoint inhibitor therapy. J. Immunother. Cancer 8, e000104 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2826_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.21971","volume":"107","author":"JD Tward","year":"2006","unstructured":"Tward, J. D., Wendland, M. M., Shrieve, D. C., Szabo, A. & Gaffney, D. K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107, 108\u2013115 (2006).","journal-title":"Cancer"},{"key":"2826_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2826_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","volume":"33","author":"G Ghilardi","year":"2022","unstructured":"Ghilardi, G. et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann. Oncol. 33, 916\u2013928 (2022).","journal-title":"Ann. Oncol."},{"key":"2826_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood.2019001859","volume":"135","author":"M Ruella","year":"2020","unstructured":"Ruella, M. et al. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. Blood 135, 505\u2013509 (2020).","journal-title":"Blood"},{"key":"2826_CR36","doi-asserted-by":"publisher","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02767-w (2024).","DOI":"10.1038\/s41591-023-02767-w"},{"key":"2826_CR37","doi-asserted-by":"publisher","unstructured":"Banerjee, R. et al. Answering the \"Doctor, can CAR-T therapy cause cancer?\" question in clinic. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2023012336 (2024).","DOI":"10.1182\/bloodadvances.2023012336"},{"key":"2826_CR38","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","volume":"5","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy, K. et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 5, e609\u2013e617 (2018).","journal-title":"Lancet Haematol."},{"key":"2826_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"2826_CR40","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2826_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"2826_CR42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2826_CR43","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.18632\/oncotarget.28309","volume":"13","author":"DJ Landsburg","year":"2022","unstructured":"Landsburg, D. J. et al. Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas. Oncotarget 13, 1237\u20131244 (2022).","journal-title":"Oncotarget"},{"key":"2826_CR44","doi-asserted-by":"publisher","first-page":"100090","DOI":"10.1016\/j.acpath.2023.100090","volume":"10","author":"DL Aisner","year":"2023","unstructured":"Aisner, D. L. et al. The Genomics Organization for Academic Laboratories (GOAL): a vision for a genomics future for academic pathology. Acad. Pathol. 10, 100090 (2023).","journal-title":"Acad. Pathol."},{"key":"2826_CR45","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1182\/bloodadvances.2023011384","volume":"7","author":"DJ Landsburg","year":"2023","unstructured":"Landsburg, D. J. et al. TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era. Blood Adv. 7, 7243\u20137253 (2023).","journal-title":"Blood Adv."},{"key":"2826_CR46","first-page":"169","volume":"6","author":"V Luo","year":"2001","unstructured":"Luo, V. et al. Detection of clonal T-cell receptor \u03b3 gene rearrangements using fluorescent-based PCR and automated high-resolution capillary electrophoresis. Mol. Diagn. 6, 169\u2013179 (2001).","journal-title":"Mol. Diagn."},{"key":"2826_CR47","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2826_CR48","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller, K. T. et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130, 2317\u20132325 (2017).","journal-title":"Blood"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02826-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T01:26:51Z","timestamp":1731115611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02826-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2826"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02826-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.G. served as a scientific consultant for viTToria Biotherapeutics. M.R. holds patents related to CD19 CAR T cells, served as a consultant for NanoString, Bristol Myers Squibb, GlaxoSmithKline, Scaylite, Bayer and AbClon; and receives research funding from AbClon, NanoString, Oxford NanoImaging, viTToria Biotherapeutics, CURIOX and Beckman Coulter. M.R. is the scientific founder of viTToria Biotherapeutics. J.S. served as a consultant for Genmab, Adaptive, AstraZeneca, BMS, ADCT, Atara, Pharmacyclics and Seattle Genetics and received research funding from AstraZeneca, BMS, Incyte, Merck, Seattle Genetics, Pharmacyclics and TG Therapeutics. G.C.C. served as a consultant for DAVA Oncology and GLG consulting. E.A.C. served as a consultant for AstraZeneca, Novartis, Beigene, KITE and Juno\/BMS and received research funding from Abbvie and Genentech\/Roche. S.K.B. served as a consultant to Acrotech, Affimed, Kyowa Kirin, Daiichi Sankyo, Janssen and Seagen. S.D.N. received research funding from Pharmacyclics, Roche, Rafael and FortySeven\/Gilead. J.D.L. received research funding from Curis, Takeda and Triphase and served on the Board of Directors, advisory committees and data and safety monitoring board for Incyte, ADCT, Karyopharm and Morphosis. S.J.S. served as a consultant to AstraZeneca, BeiGene, Celgene, Genentech, Genmab, Fate Therapeutics, Roche, Incyte, Juno Therapeutics, Legend Biotech, Loxo Oncology, MorphoSys, Mustang Biotech, Nordic Nanovector, Novartis and Regeneron; received research funding from AbbVie, Adaptive Biotechnologies, Celgene, DTRM, Genentech, Roche, Juno Therapeutics, Merck, Novartis, Incyte, Pharmacyclics and TG Therapeutics; received honoraria from Celgene and Novartis; and holds patents related to CD19 CAR T cells and autologous co-stimulated T cells. D.L.P. declares funding from the National Marrow Donor Program; membership on an entity\u2019s Board of Directors or advisory committees of Kite\/Gilead, Janssen, Genentech, DeCart, Sana Biotechnology, Verisimo and Novartis; is a current equity holder of the American Society for Transplantation and Cellular Therapy and Verismo; declares honoraria for Incyte; patents and royalties in Tmunity and Wiley and Sons Publishing. A.L.G. declares research support from Janssen, Novartis, Tmunity and CRISPR Therapeutics; consultancies\/honoraria from Janssen, Novartis, BMS, GSK and Legend Bio; and DSMB membership for Janssen. C.H.J. and the University of Pennsylvania have patents pending or issued related to the use of gene modification in T cells for adoptive T cell therapy. C.H.J. is a co-founder of Tmunity, is a scientific co-founder and holds equity in Capstan Therapeutics, Dispatch Biotherapeutics and Bluewhale Bio. C.H.J. serves on the board of AC Immune and is a scientific advisor to BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta, Vittoria Bio and WIRB-Copernicus group. C.H.J. is an inventor on patents and\/or patent applications licensed to Novartis Institutes of Biomedical Research and Kite and may receive license revenue from such licenses. J.A.F. is a member of the Scientific Advisory Boards of Cartography Bio and Shennon Biotechnologies and has patents, royalties and other intellectual property. B.L.L. reports personal fees from Akron, Avectas, Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, Thermo Fisher Pharma Services, UTC Therapeutics and Vycellix and is a co-founder and equity holder in Tmunity Therapeutics (acquired by Kite Pharma) and Capstan Therapeutics. N.V.F. declares an affiliation with Sana Biotechnology; consultancy roles for Novartis and Syndax Pharmaceuticals; and research funding from Kite Pharma. E.A.S. declares an affiliation with Oncopeptides; consultancy for Amgen, BMS Celgene, G.S.K., Janssen and AbbVie. E.O.H. declares an affiliation with Tmunity Therapeutics and research funding from Blueprint Medicines and PharmaEssentia; membership on an entity\u2032s Board of Directors or advisory committees for Blueprint Medicines and PharmaEssentia. D.T.V. has received research funding from Takeda and Active Biotech and consulting fees from Takeda, Karyopharm, GSK, Genentech and Sanofi. A.D.C. is a scientific advisor for Janssen and BMS and has received research support and royalties from Novartis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}